Back to Directory

Levodopa

L-DOPA

Visual ViewRaw DataInteraction Data

Meta Information

ID:levodopa
Name:Levodopa
Schema Version:1.5

Alternate Names

  • L-DOPA

Active Compound

levodopa

Intervention Type

therapeutic_agent

Delivery

Route:
oral
Scope:
  • systemic

Regulatory Status

  • us:rx_drug
  • eu:rx_drug

Indication

Focus:
disease_treatment
Description:
Treatment of motor symptoms associated with Parkinson's disease and dopamine-responsive dystonia.

Typical Protocol

  • Initial doses are typically low, around 50-100 mg taken 1-3 times per day.
  • Dosage is gradually titrated upwards by a physician based on clinical response and side effects.
  • Almost always co-administered with a DOPA decarboxylase inhibitor like carbidopa or benserazide to increase efficacy and reduce side effects.

Expected Cost Mean

Low Cost:
20
High Cost:
200
Cost Type:
monthly
Description:
Generic versions are often affordable; typically covered by insurance for indicated conditions.

Summary

Levodopa is a metabolic precursor to the neurotransmitter dopamine. It crosses the blood-brain barrier and is converted into dopamine, replenishing depleted levels in the brains of individuals with Parkinson's disease. This action directly alleviates motor symptoms like tremors, rigidity, and slowness of movement, making it the most effective symptomatic therapy for the condition.

Purpose

Restores brain dopamine levels to treat Parkinson's disease motor symptoms.

Card Summary

A precursor to dopamine, used as a primary treatment to manage motor symptoms of Parkinson's disease.

Drug Class

dopamine_precursor

Drugs In Class

Empty Array

Impact

Score:
8.5
Justification:
Gold-standard, highly effective symptomatic treatment for motor symptoms of Parkinson's disease.

Evidence

Grade:
A
Score:
9.8
Justification:
Decades of extensive, high-quality human RCTs and meta-analyses confirm its efficacy.

Safety

Score:
7.2
Justification:
Significant long-term side effects like dyskinesias and motor fluctuations require careful management.

Flags

  • Long-term use is associated with motor complications, including dyskinesias (involuntary movements) and 'on-off' fluctuations.
  • Common side effects include nausea, dizziness, and orthostatic hypotension.
  • May cause psychiatric side effects such as hallucinations, confusion, and impulse control disorders.
  • Should not be used for any healthspan purpose due to its significant side effect profile.
  • Interacts with non-selective MAO inhibitors, antipsychotics, and certain antihypertensives.

Verdict

Essential for Parkinson's treatment; inappropriate and risky for healthspan purposes.

Created

2026-04-30T01:27:21.797568Z

Ai Model

Gemini 2.5 Pro (High)

Non Healthspan

True